Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 11, 2015, Pages 1591-1595

  Andrade, Patrícia ^a   Santos Antunes, João ^a,b   Rodrigues, Susana ^a   Lopes, Susana ^a   Macedo, Guilherme ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Biologic therapies; HBV vaccine efficacy; Hepatitis B; IBD: clinical trials < gastroenterology; Immunomodulators; Virology < hepatology

Indexed keywords

AZATHIOPRINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; INFLIXIMAB; GASTROINTESTINAL AGENT; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; COLITIS; CROHN DISEASE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PANCOLITIS; PRIORITY JOURNAL; PROCTITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; VACCINATION; ADOLESCENT; BLOOD; COLITIS, ULCERATIVE; DRUG INTERACTION; IMMUNOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; YOUNG ADULT;

EID: 84943637543     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13001     Document Type: Article

References (35)

1. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-1925.
2. Moum B. Medical treatment: does it influence the natural course of inflammatory bowel disease? Eur. J. Intern. Med. 2000; 11: 197-203.
3. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm. Bowel Dis. 2010; 16: 925-932.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
5. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 33: 619-633.
6. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, etal. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm. Bowel Dis. 2004; 10: 701-702.
7. Esteve M, Saro C, Gonzalez-Huix F, etal. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
8. Millonig G, Kern M, Ludwiczek O, etal. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J. Gastroenterol. 2006; 12: 974-976.
9. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 2007; 13: 1453-1454.
10. Madonia S, Orlando A, Scimeca D, etal. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm. Bowel Dis. 2007; 13: 508-509.
11. Loras C, Gisbert JP, Minguez M etal. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.
12. Viget N, Vernier-Massouille G, Salmon-Ceron D, etal. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558
13. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 2009; 15: 1410-1416
14. Rahier JF, Ben-Horin S, Chowers Y, etal. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2009; 3: 47-91.
15. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am. J. Gastroenterol. 2010; 105: 1231-1238
16. Melmed GY, Ippoliti AF, Papadakis KA, etal. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol. 2006; 101: 1834-1840.
17. Loras C, Saro C, Gonzalez-Huix F, etal. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am. J. Gastroenterol. 2009; 104: 57-63.
18. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, etal. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med. Clin. (Barc) 2009; 132: 331-335.
19. Altunoz ME, Senates E, Yesil A, etal. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig. Dis. Sci. 2012; 57: 1039-1044.
20. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2012; 107: 1460-1466.
21. Jung YS, Park JH, Kim HJ, etal. Insufficient knowledge of Korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease. Gut Liver 2014; 8: 242-247
22. Mast EE, Weinbaum CM, Fiore AE, etal. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm. Rep. 2006; 55: 1-33.
23. World Health Organization. Publication. Hepatitis B vaccines. WHO position paper-recommendations. Vaccine 2009; 28: 589-590.
24. Chaparro M, Villagrasa JR, Rodríguez Nogueiras A, Gisbert JP. Immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology 2010; 138: S197.
25. Dotan I, Werner L, Vigodman S, etal. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm. Bowel. Dis. 2012; 18: 261-268.
26. Jack AD, Hall AJ, Maine N, etal. What level of hepatitis B antibody is protective? J. Infect. Dis. 1999; 179: 489-492.
27. Chevaux JB, Nani A, Oussalah A, etal. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm. Bowel Dis. 2010; 16: 916-924.
28. Zuckerman JN, Sabin C, Craig FM, etal. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomized double blind dose-response study. BMJ 1997; 314: 329-333.
29. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
30. Worns MA, Teufel A, Kanzler S, etal. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol. 2008; 103: 138-146.
31. Shaye OA, Yadegari M, Abreu MT, etal. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am. J. Gastroenterol. 2007; 102: 2488-2494.
32. Tiede I, Fritz G, Strand S, etal. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4{thorn} T lymphocytes. J. Clin. Invest. 2003; 111: 1133-1145.
33. Gelinck LB, van der Bijl AE, Beyer WE etal. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 2008; 67: 713-716.
34. Mamula P, Markowitz JE, Piccoli DA etal. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007; 5: 851-856.
35. Lu Y, Jacobson DL, Ashworth LA etal. Immune response to influenza vaccine in children with inflammatory bowel disease. Am. J. Gastroenterol. 2009; 104: 444-453.